论文部分内容阅读
本文对TIL与LAK细胞的体外,体内抗肿瘤作用进行了比较。发现TIL对自体肿瘤细胞有选择性地杀伤作用,其杀伤活性强于LAK细胞,但TIL对其他无关的肿瘤细胞的杀伤作用弱于LAK细胞,其对ConA诱导的正常淋巴母细胞无杀伤作用,而LAK细胞对比正常细胞有一定的杀伤作用。能特异性阻断抗B16黑色素瘤细胞CTL活性的单抗能抑制来自B16黑色素瘤的TIL对B16细胞的杀伤作用,提示TIL中富含CTL。体内试验证明,就单个细胞能力来讲,TIL的抗肿瘤作用确比LAK细胞强且对LAK细胞治疗无效的晚期肿瘤仍有一定的治疗效果。本研究证明TIL比LAK细胞更适合应用于肿瘤的过继免疫疗法。
In this paper, TIL and LAK cells in vitro and in vivo antitumor effects were compared. TIL was found to have a selective killing effect on autologous tumor cells and its killing activity was stronger than that of LAK cells. However, TIL had less cytotoxic effects on other unrelated tumor cells than LAK cells and had no killing effect on ConA-induced normal lymphoblasts. The LAK cells compared to normal cells have a certain killing effect. Monoclonal antibodies that specifically blocked CTL activity against B16 melanoma cells inhibited the killing effect of TIL from B16 melanoma on B16 cells, suggesting that CTLs are abundant in TILs. In vivo experiments show that the antitumor effect of TIL is indeed a single treatment of advanced tumors that are more potent than LAK cells and ineffective in LAK cell therapy in terms of individual cell competence. This study demonstrates that TIL is more suitable for adoptive immunotherapy of tumors than LAK cells.